Development of an Artificial Intelligence Model for the Identification and Prevention of Smoking-related Diseases.

NCT ID: NCT06626178

Last Updated: 2024-10-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

2840 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-10-01

Study Completion Date

2028-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is an interventional pilot study. The study is designed to be monocentric and it presents additional procedues.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Interventional pilot study, single-center with additional procedures, such as completion of EORTC-QLQ-LC29, EORTC-QLQ-C30 questionnaires, motivational test, Fagestrom test, anamnestic questionnaire, spirometry, measurement of carbon monoxide, Low-dose spiral computed tomography without contrast medium, peripheral venous blood sampling for a volume of 20 ml.

The study has the main objective of traininig and validate a reliable and unbiased Artificial Intelligence (AI) algorithm that detects the presence of nodules and differentiates between malignant or benign tumor types.

The study considers patients with suspected diagnosis or with a dignosis of lung cancer, smokers and former smokers over 50 years of age at high risk of lung cancer and subjects enrolled in previous screening cohorts at this Institute.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer Screening Program Artificial Intelligence (AI)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

In the study are considered 4 different cohorts. Lung cancer patients diagnosed outside screening and treated at San Raffaele Hospital; smokers and former smokers aged over 50 years old at high risk for lung cancer, cardiovascular diseases and chronic obstructive pulmonary disease (COPD); subjects enrolled in previous screening cohorts in this Institute, which presented a computed tomography (CT) with the presence of lung nodules \>4 mm and to conclude, subjects enrolled in previous screening cohorts in this Institute, which presented a negative computed tomography (CT).
Primary Study Purpose

SCREENING

Blinding Strategy

NONE

No blinding in this study

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

High-risk screening subjects

Ever and former male and female smokers aged over 50 years old at high risk for lung cancer, cardiovascular diseases and chronic obstructive pulmonary disease (COPD).

Additional procedures for this group:

* Spirometry
* Nurse evaluation
* Epidemiological questionnaire, Quality of Life (QoL) questionnaires
* Smoking cessation program
* Cardiovascular primary prevention
* measurement of carbon monoxide (CO)
* Blood storage
* Computed tomography (CT) scan low-dose

Group Type EXPERIMENTAL

Computed tomography (CT) scan low dose

Intervention Type DIAGNOSTIC_TEST

The radiological investigation will be done with multi-detector-row (64 or more) computed tomography (CT) scanners at low-dose protocol. The low-dose spiral CT consists of a CT study of the chest, without the need for injection of contrast medium, characterized by less radio exposure than the standard CT of the chest with high sensitivity in detecting pulmonary nodules.

Blood sampling

Intervention Type PROCEDURE

Peripheral venous blood sampling (20 ml)

Spirometry

Intervention Type OTHER

Spirometry measurement using spirometer

Questionnaires

Intervention Type OTHER

Compilation of epidemiological questionnaire, quality of life questionnaires

Smoking cessation program

Intervention Type OTHER

Study guarantee valid support for quitting smoking, which for a smoker is a more effective intervention to reduce the risk of developing lung cancer, myocardial infarction and other smoking-related diseases

Carbon monoxide measurment

Intervention Type OTHER

Measurment of Carbon monoxide (CO)

Cardiovascular primary prevention

Intervention Type OTHER

Intervention done in order to find the presence of coronary calcifications

Previous positive high-risk screening subjects

Subjects enrolled in previous screening cohorts in this Institute with the presence of lung nodules \>4 mm. Additional procedure for this group: Computed tomography (CT) scan low-dose

Group Type EXPERIMENTAL

Computed tomography (CT) scan low dose

Intervention Type DIAGNOSTIC_TEST

The radiological investigation will be done with multi-detector-row (64 or more) computed tomography (CT) scanners at low-dose protocol. The low-dose spiral CT consists of a CT study of the chest, without the need for injection of contrast medium, characterized by less radio exposure than the standard CT of the chest with high sensitivity in detecting pulmonary nodules.

Smoking cessation program

Intervention Type OTHER

Study guarantee valid support for quitting smoking, which for a smoker is a more effective intervention to reduce the risk of developing lung cancer, myocardial infarction and other smoking-related diseases

Previous negative high-risk screening subjects

Subjects enrolled in previous screening cohorts in this Institute with negative computed tomography (CT) scan. No additional procedures for this group.

Group Type NO_INTERVENTION

No interventions assigned to this group

Lung cancer patients

Lung cancer patients diagnosed outside screening and treated at San Raffaele Hospital. Additional procedures for this group: biobank tissue and blood storage.

Group Type EXPERIMENTAL

Blood sampling

Intervention Type PROCEDURE

Peripheral venous blood sampling (20 ml)

Tissue sampling (lung)

Intervention Type PROCEDURE

sampling of tumor and healthy tissue during surgery

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Computed tomography (CT) scan low dose

The radiological investigation will be done with multi-detector-row (64 or more) computed tomography (CT) scanners at low-dose protocol. The low-dose spiral CT consists of a CT study of the chest, without the need for injection of contrast medium, characterized by less radio exposure than the standard CT of the chest with high sensitivity in detecting pulmonary nodules.

Intervention Type DIAGNOSTIC_TEST

Blood sampling

Peripheral venous blood sampling (20 ml)

Intervention Type PROCEDURE

Tissue sampling (lung)

sampling of tumor and healthy tissue during surgery

Intervention Type PROCEDURE

Spirometry

Spirometry measurement using spirometer

Intervention Type OTHER

Questionnaires

Compilation of epidemiological questionnaire, quality of life questionnaires

Intervention Type OTHER

Smoking cessation program

Study guarantee valid support for quitting smoking, which for a smoker is a more effective intervention to reduce the risk of developing lung cancer, myocardial infarction and other smoking-related diseases

Intervention Type OTHER

Carbon monoxide measurment

Measurment of Carbon monoxide (CO)

Intervention Type OTHER

Cardiovascular primary prevention

Intervention done in order to find the presence of coronary calcifications

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \>= 50 years old
* Active smokers
* Former smokers (from no more than 15 years)
* Pack/year \>20
* Risk-prediction model from Prostate, Lung, Colorectal, and Ovarian study (PLCOm2012) \>1.2%
* Provision and signature of informed consent


* Subjects enrolled in previous lung cancer screening with the presence of lung nodules \>4 mm and candidate to additional computed tomography (CT)
* Signed informed consent


* Subjects enrolled in previous lung cancer screening in this Institute with negative computed tomography (CT)
* Signed informed consent


* Patients with diagnosis or suspicious diagnosis of lung cancer candidate to surgical treatment or already submitted to it
* Patients with diagnosis of lung cancer treated with surgical resection
* Signed informed consent

Exclusion Criteria

* Previous or concurrent neoplastic disease, excluding skin cancers
* Cognitive or other problems that could hinder the collection of informed consent
* Severe pulmonary or extra pulmonary disease
* Previous low-dose computed tomography (CT) scan in the past 12 months

Previous high-risk positive screening subjects


\- None

Previous high-risk negative screening subjects


\- None

Lung Cancer patients


* computed tomography (CT) scans not available at San Raffaele Hospital
* Previous neoadjuvant treatment
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Scientific Institute San Raffaele

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Muriana Piergiorgio

Medical Doctor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Scientific Institute Ospedale San Raffaele

Milan, , Italy

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Italy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Piergiorgio Muriana, MD

Role: CONTACT

0226437232 ext. +39

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Piergiorgio Muriana, MD

Role: primary

0226437232 ext. +39

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CET 288-2024

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Smoking Cessation Study
NCT05602753 UNKNOWN
Mobile Sensing of Smoking Behavior
NCT02116283 COMPLETED NA